Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity

Journal of Virology

Volumn 85, Issue 16, 2011, Pages 8197-8207

  Li, Melody M H ^a,b   Emerman, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING CATALYTIC POLYPEPTIDE; CYTIDINE DEAMINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; APOBEC3H GENE; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STABILITY;

EID: 79961190975     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00624-11     Document Type: Article

References (31)

1. Albin, J. S., and R. S. Harris. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert. Rev. Mol. Med. 12:e4.
2. Bishop, K. N., et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
3. Bishop, K. N., M. Verma, E. Y. Kim, S. M. Wolinsky, and M. H. Malim. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e1000231.
4. Bogerd, H. P., et al. 2006. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103:8780-8785.
5. Conticello, S. G., C. J. Thomas, S. K. Petersen-Mahrt, and M. S. Neuberger. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22:367-377.
6. Gallois-Montbrun, S., et al. 2008. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J. Virol. 82:5636-5642.
7. Gourraud, P. A., et al. 2011. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum. Immunol. 72:207-212.
8. Harari, A., M. Ooms, L. C. Mulder, and V. Simon. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303.
9. Kinomoto, M., et al. 2007. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 35:2955-2964.
10. Kutay, U., and S. Güttinger. 2005. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol. 15:121-124.
11. LaRue, R. S., S. R. Jónsson, et al. 2008. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9:104.
12. Li, M., L. Wu, and M. Emerman. 2010. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 84:88-95.
13. Malim, M. H., and M. Emerman. 2008. HIV-1 accessory proteins: ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398.
14. Mehle, A., et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
15. Mingot, J. M., M. T. Bohnsack, U. Jäkle, and D. Görlich. 2004. Exportin 7 defines a novel general nuclear export pathway. EMBO J. 23:3227-3236.
16. Muckenfuss, H., et al. 2006. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281:22161-22172.
17. OhAinle, M., J. A. Kerns, M. M. Li, H. S. Malik, and M. Emerman. 2008. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:249-259.
18. OhAinle, M., J. A. Kerns, H. S. Malik, and M. Emerman. 2006. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80:3853-3862.
19. Ooms, M., S. Majdak, C. Seibert, A. Harari, and V. Simon. 2010. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 84:7961-7969.
20. Refsland, E. W., et al. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
21. Sawyer, S. L., M. Emerman, and H. S. Malik. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2:E275.
22. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
23. Stenglein, M. D., H. Matsuo, and R. S. Harris. 2008. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 82:9591-9599.
24. Tan, L., P. T. Sarkis, T. Wang, C. Tian, and X. F. Yu. 2009. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23:279-287.
25. Thielen, B. K., et al. 2007. T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog. 3:1320-1334.
26. Wang, X., et al. 2011. Analysis of human APOBEC3H haplotypes and antihuman immunodeficiency virus type 1 activity. J. Virol. 85:3142-3152.
27. Wente, S. R., and M. P. Rout. 2010. The nuclear pore complex and nuclear transport. Cold Spring Harb. Perspect. Biol. 2:a00562.
28. Yamashita, M., and M. Emerman. 2004. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78:5670-5678.
29. Yu, X., et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
30. Zhen, A., T. Wang, K. Zhao, Y. Xiong, and X. Yu. 2010. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84:1902-1911.
31. Zielonka, J., et al. 2009. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J. Virol. 83:7547-7559.